Search

Your search keyword '"Souleymane, M.B."' showing total 5 results
Start Over Author "Souleymane, M.B."
5 results on '"Souleymane, M.B."'

1. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort

Author

Koirala, S., Borisov, S., Danila, E., Mariandyshev, A., Shrestha, B., Lukhele, N., Dalcolmo, M., Shakya, S.R., Miliauskas, S., Kuksa, L., Manga, S., Aleksa, A., Denholm, J.T., Khadka, H.B., Skrahina, A., Diktanas, S., Ferrarese, M., Bruchfeld, J., Koleva, A., Piubello, A., Koirala, G.S., Udwadia, Z.F., Palmero, D.J., Munoz-Torrico, M., GC, R., Gualano, G., Grecu, V.I., Motta, I., Papavasileiou, A., Li, Y., Hoefsloot, W., Kunst, H., Mazza-Stalder, J., Payen, M.-C., Akkerman, O.W., Bernal, E., Manfrin, V., Matteelli, A., Mustafa Hamdan, H., Nieto Marcos, M., Cadiñanos Loidi, J., Cebrian Gallardo, J.J., Duarte, R., Escobar Salinas, N., Gomez Rosso, R., Laniado-Laborín, R., Martínez Robles, E., Quirós Fernandez, S., Rendon, A., Solovic, I., Tadolini, M., Viggiani, P., Belilovski, E., Boeree, M.J., Cai, Q., Davidavičienė, E., Forsman, L.D., De Los Rios, J., Drakšienė, J., Duga, A., Elamin, S.E., Filippov, A., Garcia, A., Gaudiesiute, I., Gavazova, B., Gayoso, R., Gruslys, V., Jonsson, J., Khimova, E., Madonsela, G., Magis-Escurra, C., Marchese, V., Matei, M., Moschos, C., Nakčerienė, B., Nicod, L., Palmieri, F., Pontarelli, A., Šmite, A., Souleymane, M.B., Vescovo, M., Zablockis, R., Zhurkin, D., Alffenaar, J.-W., Caminero, J.A., Codecasa, L.R., García-García, J.-M., Esposito, S., Saderi, L., Spanevello, A., Visca, D., Tiberi, S., Pontali, E., Centis, R., D'Ambrosio, L., van den Boom, M., Sotgiu, G., and Migliori, G.B.

Published
2021
Full Text
View/download PDF

2. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report

Author

Borisov, S., Danila, E., Maryandyshev, A., Dalcolmo, M., Miliauskas, S., Kuksa, L., Manga, S., Skrahina, A., Diktanas, S., Codecasa, L.R., Aleksa, A., Bruchfeld, J., Koleva, A., Piubello, A., Udwadia, Z.F., Akkerman, O.W., Belilovski, E., Bernal, E., Boeree, M.J., Loidi, J., Cai, Q., Gallardo, J.J. Cebrian, Dara, M., Davidaviciene, E., Forsman, L.D., Rios, J. De Los, Denholm, J., Draksiene, J., Duarte, R., Elamin, S.E., Salinas, N. Escobar, Ferrarese, M., Filippov, A., Garcia, A., Garcia-Garcia, J.M., Gaudiesiute, I., Gavazova, B., Gayoso, R., Rosso, R., Gruslys, V., Gualano, G., Hoefsloot, W., Jonsson, J., Khimova, E., Kunst, H., Laniado-Laborin, R., Li, Y, Magis-Escurra, C., Manfrin, V., Marchese, V., Robles, E. Martinez, Matteelli, A., Mazza-Stalder, J., Moschos, C., Munoz-Torrico, M., Hamdan, H. Mustafa, Nakceriene, B., Nicod, L., Marcos, M., Palmero, D.J., Palmieri, F., Papavasileiou, A., Payen, M.C., Pontarelli, A., Quiros, S., Rendon, A., Saderi, L., Smite, A., Solovic, I., Souleymane, M.B., Tadolini, M., Boom, M. van den, Vescovo, M., Viggiani, P., Yedilbayev, A., Zablockis, R., Zhurkin, D., Zignol, M., Visca, D., Spanevello, A., Caminero, J.A., Alffenaar, J.W.C., Tiberi, S., Centis, R., D'Ambrosio, L., Pontali, E., Sotgiu, G., Migliori, G.B., Borisov, S., Danila, E., Maryandyshev, A., Dalcolmo, M., Miliauskas, S., Kuksa, L., Manga, S., Skrahina, A., Diktanas, S., Codecasa, L.R., Aleksa, A., Bruchfeld, J., Koleva, A., Piubello, A., Udwadia, Z.F., Akkerman, O.W., Belilovski, E., Bernal, E., Boeree, M.J., Loidi, J., Cai, Q., Gallardo, J.J. Cebrian, Dara, M., Davidaviciene, E., Forsman, L.D., Rios, J. De Los, Denholm, J., Draksiene, J., Duarte, R., Elamin, S.E., Salinas, N. Escobar, Ferrarese, M., Filippov, A., Garcia, A., Garcia-Garcia, J.M., Gaudiesiute, I., Gavazova, B., Gayoso, R., Rosso, R., Gruslys, V., Gualano, G., Hoefsloot, W., Jonsson, J., Khimova, E., Kunst, H., Laniado-Laborin, R., Li, Y, Magis-Escurra, C., Manfrin, V., Marchese, V., Robles, E. Martinez, Matteelli, A., Mazza-Stalder, J., Moschos, C., Munoz-Torrico, M., Hamdan, H. Mustafa, Nakceriene, B., Nicod, L., Marcos, M., Palmero, D.J., Palmieri, F., Papavasileiou, A., Payen, M.C., Pontarelli, A., Quiros, S., Rendon, A., Saderi, L., Smite, A., Solovic, I., Souleymane, M.B., Tadolini, M., Boom, M. van den, Vescovo, M., Viggiani, P., Yedilbayev, A., Zablockis, R., Zhurkin, D., Zignol, M., Visca, D., Spanevello, A., Caminero, J.A., Alffenaar, J.W.C., Tiberi, S., Centis, R., D'Ambrosio, L., Pontali, E., Sotgiu, G., and Migliori, G.B.

Abstract

Item does not contain fulltext, The World Health Organization (WHO) recommends that countries implement pharmacovigilance and collect information on active drug safety monitoring (aDSM) and management of adverse events.The aim of this prospective study was to evaluate the frequency and severity of adverse events to anti-tuberculosis (TB) drugs in a cohort of consecutive TB patients treated with new (i.e. bedaquiline, delamanid) and repurposed (i.e. clofazimine, linezolid) drugs, based on the WHO aDSM project. Adverse events were collected prospectively after attribution to a specific drug together with demographic, bacteriological, radiological and clinical information at diagnosis and during therapy. This interim analysis included patients who completed or were still on treatment at time of data collection.Globally, 45 centres from 26 countries/regions reported 658 patients (68.7% male, 4.4% HIV co-infected) treated as follows: 87.7% with bedaquiline, 18.4% with delamanid (6.1% with both), 81.5% with linezolid and 32.4% with clofazimine. Overall, 504 adverse event episodes were reported: 447 (88.7%) were classified as minor (grade 1-2) and 57 (11.3%) as serious (grade 3-5). The majority of the 57 serious adverse events reported by 55 patients (51 out of 57, 89.5%) ultimately resolved. Among patients reporting serious adverse events, some drugs held responsible were discontinued: bedaquiline in 0.35% (two out of 577), delamanid in 0.8% (one out of 121), linezolid in 1.9% (10 out of 536) and clofazimine in 1.4% (three out of 213) of patients. Serious adverse events were reported in 6.9% (nine out of 131) of patients treated with amikacin, 0.4% (one out of 221) with ethionamide/prothionamide, 2.8% (15 out of 536) with linezolid and 1.8% (eight out of 498) with cycloserine/terizidone.The aDSM study provided valuable information, but implementation needs scaling-up to support patient-centred care.

Published
2019

3. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study

Author

Akkerman, O., Aleksa, A., Alffenaar, J.W.C., Al-Marzouqi, N.H., Arias-Guillen, M., Belilovski, E., Bernal, E., Boeree, M.J., Borisov, S.E., Bruchfeld, J., Loidi, J., Cai, Q., Caminero, J.A., Gallardo, J.J. Cebrian, Centis, R., Codecasa, L.R., D'Ambrosio, L., Dalcolmo, M., Danila, E., Dara, M., Davidaviciene, E., Forsman, L. Davies, Jefe, J. De Los Rios, Denholm, J., Duarte, R., Elamin, S.E., Ferrarese, M., Filippov, A., Ganatra, S., Garcia, A., Garcia-Garcia, J.M., Gayoso, R., Montoya, A.M. Giraldo, Rosso, R.G. Gomez, Gualano, G., Hoefsloot, W., Ilievska-Poposka, B., Jonsson, J., Khimova, E., Kuksa, L., Kunst, H., Laniado-Laborin, R., Li, Y., Magis-Escurra, C., Manfrin, V., Manga, S., Marchese, V., Robles, E. Martinez, Maryandyshev, A., Matteelli, A., Migliori, G.B., Mullerpattan, J.B., Munoz-Torrico, M., Hamdan, H. Mustafa, Marcos, M., Noordin, N.M., Palmero, D.J., Palmieri, F., Payen, M.C., Piubello, A., Pontali, E., Pontarelli, A., Quiros, S., Rendon, A., Skrahina, A., Smite, A., Solovic, I., Sotgiu, G., Souleymane, M.B., Spanevello, A., Stosic, M., Tadolini, M., Tiberi, S., Udwadia, Z.F., Boom, M. van den, Vescovo, M., Viggiani, P., Visca, D., Zhurkin, D., Zignol, M., Akkerman, O., Aleksa, A., Alffenaar, J.W.C., Al-Marzouqi, N.H., Arias-Guillen, M., Belilovski, E., Bernal, E., Boeree, M.J., Borisov, S.E., Bruchfeld, J., Loidi, J., Cai, Q., Caminero, J.A., Gallardo, J.J. Cebrian, Centis, R., Codecasa, L.R., D'Ambrosio, L., Dalcolmo, M., Danila, E., Dara, M., Davidaviciene, E., Forsman, L. Davies, Jefe, J. De Los Rios, Denholm, J., Duarte, R., Elamin, S.E., Ferrarese, M., Filippov, A., Ganatra, S., Garcia, A., Garcia-Garcia, J.M., Gayoso, R., Montoya, A.M. Giraldo, Rosso, R.G. Gomez, Gualano, G., Hoefsloot, W., Ilievska-Poposka, B., Jonsson, J., Khimova, E., Kuksa, L., Kunst, H., Laniado-Laborin, R., Li, Y., Magis-Escurra, C., Manfrin, V., Manga, S., Marchese, V., Robles, E. Martinez, Maryandyshev, A., Matteelli, A., Migliori, G.B., Mullerpattan, J.B., Munoz-Torrico, M., Hamdan, H. Mustafa, Marcos, M., Noordin, N.M., Palmero, D.J., Palmieri, F., Payen, M.C., Piubello, A., Pontali, E., Pontarelli, A., Quiros, S., Rendon, A., Skrahina, A., Smite, A., Solovic, I., Sotgiu, G., Souleymane, M.B., Spanevello, A., Stosic, M., Tadolini, M., Tiberi, S., Udwadia, Z.F., Boom, M. van den, Vescovo, M., Viggiani, P., Visca, D., Zhurkin, D., and Zignol, M.

Abstract

Contains fulltext : 207083.pdf (publisher's version ) (Open Access), The World Health Organization launched a global initiative, known as aDSM (active TB drug safety monitoring and management) to better describe the safety profile of new treatment regimens for drug-resistant tuberculosis (TB) in real-world settings. However, comprehensive surveillance is difficult to implement in several countries. The aim of the aDSM project is to demonstrate the feasibility of implementing national aDSM registers and to describe the type and the frequency of adverse events (AEs) associated with exposure to the new anti-TB drugs. Following a pilot study carried out in 2016, official involvement of TB reference centres/countries into the project was sought and cases treated with bedaquiline- and/or delamanid-containing regimens were consecutively recruited. AEs were prospectively collected ensuring potential attribution of the AE to a specific drug based on its known safety profile. A total of 309 cases were fully reported from 41 centres in 27 countries (65% males; 268 treated with bedaquiline, 20 with delamanid, and 21 with both drugs) out of an estimated 781 cases the participating countries had committed to report by the first quarter of 2019.

Published
2019

4. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020

Author

Matteo Saporiti, José-María García-García, Fabrizio Palmieri, Paola Scognamiglio, Fernando Álvarez-Navascués, Luigi Codecasa, Michel Eke Tchangou, Alberto Piubello, Zarir F Udwadia, Fernanda Carvalho de Queiroz Mello, Paola Castellotti, Andrei Maryandyshev, Gina Gualano, Alice Boi Yatta Thornton, José Antonio Gullón-Blanco, Tatiana Senna Galvão, Pascale Valérie Bernard, Joshua Sorba Biala, Giovanni Sotgiu, Rosella Centis, Domingo Palmero, Marina Tadolini, Samridhi Sharma, Eva Tabernero, Catherine W.M. Ong, Heinke Kunst, Adrian Rendon, Jeremiah Chakaya, Maurizio Ferrarese, Antonio Spanevello, Simon Tiberi, Elena M. Bogorodskaya, Pei Min Thong, Mario Melazzini, Martin Enwerem, Patrick Bung Njungfiyini, Marcela Muñoz-Torrico, Delia Goletti, François-Xavier Blanc, Giuseppe Ippolito, Marianne Calnan, Mahamadou Bassirou Souleymane, Giovanni Battista Migliori, Sergey Borisov, Marta García-Clemente, Mourtala Mohamed Assao-Neino, Denise Rossato Silva, Justin T Denholm, Sandra Inwentarz, Jin-Gun Cho, Lia D'Ambrosio, Jan-Willem C. Alffenaar, Onno W. Akkerman, Pavilio Piccioni, Danilo Buonsenso, Josefina Sabriá, Migliori G.B., Thong P.M., Akkerman O., Alffenaar J.-W., Alvarez-Navascues F., Assao-Neino M.M., Bernard P.V., Biala J.S., Blanc F.-X., Bogorodskaya E.M., Borisov S., Buonsenso D., Calnan M., Castellotti P.F., Centis R., Chakaya J.M., Cho J.-G., Codecasa L.R., D'Ambrosio L., Denholm J., Enwerem M., Ferrarese M., Galvao T., Garcia-Clemente M., Garcia-Garcia J.-M., Gualano G., Gullon-Blanco J.A., Inwentarz S., Ippolito G., Kunst H., Maryandyshev A., Melazzini M., Mello F.C.D.Q., Munoz-Torrico M., Njungfiyini P.B., Palmero D.J., Palmieri F., Piccioni P., Piubello A., Rendon A., Sabria J., Saporiti M., Scognamiglio P., Sharma S., Silva D.R., Souleymane M.B., Spanevello A., Tabernero E., Tadolini M., Tchangou M.E., Thornton A.B.Y., Tiberi S., Udwadia Z.F., Sotgiu G., Ong C.W.M., Goletti D., and Microbes in Health and Disease (MHD)

Subjects
Epidemiology, lcsh:Medicine, Disease, medicine.disease_cause, Global Health, 0302 clinical medicine, respiratory infection, Pandemic, wc_505, Global health, 030212 general & internal medicine, health service, Coronavirus, wa_105, biology, Dispatch, Attendance, Continuity of Patient Care, Viral/epidemiology, Infectious Diseases, TB, coronavirus disease, Coronavirus Infections, severe acute respiratory syndrome coronavirus 2, Human, Microbiology (medical), zoonose, Tuberculosis, 030231 tropical medicine, Pneumonia, Viral, lcsh:Infectious and parasitic diseases, 2019 novel coronavirus disease, respiratory infections, 03 medical and health sciences, Betacoronavirus, Environmental health, medicine, Humans, lcsh:RC109-216, viruses, Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January–April 2020, health services, Pneumonia, Viral/epidemiology, Pandemics, viruse, Global Health/trends, Betacoronaviru, business.industry, SARS-CoV-2, Coronavirus Infection, lcsh:R, COVID-19, Pneumonia, biology.organism_classification, medicine.disease, zoonoses, tuberculosis and other mycobacteria, wc_518, Continuity of Patient Care/trends, Tuberculosis/epidemiology, Coronavirus Infections/epidemiology, Facilities and Services Utilization/trends, business, Facilities and Services Utilization
Abstract

Coronavirus disease has disrupted tuberculosis services globally. Data from 33 centers in 16 countries on 5 continents showed that attendance at tuberculosis centers was lower during the first 4 months of the pandemic in 2020 than for the same period in 2019. Resources are needed to ensure tuberculosis care continuity during the pandemic.

Published
2020
Full Text
View/download PDF

5. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report

Author

José-María García-García, Jerker Jonsson, Fabrizio Palmieri, Luigi Codecasa, Matteo Zignol, Andrei Maryandyshev, Qingshan Cai, Domingo Palmero, Magnolia Nieto Marcos, Seifeldin Eltaeb Elamin, Enrique Bernal, Simon Tiberi, Alberto Matteelli, Marisa Vescovo, Judith Bruchfeld, Edita Davidavičienė, Saulius Diktanas, Skaidrius Miliauskas, Rolandas Zablockis, Raquel Duarte, R. Rosso, Martin J. Boeree, Marcela Muñoz-Torrico, Valentina Marchese, Adrian Rendon, Evgeny Belilovski, Sergey Borisov, Zarir F Udwadia, Antoniya Koleva, Jorge De Los Rios, Giovanni Battista Migliori, Ana Garcia, Elena Martínez Robles, Hamdan Mustafa Hamdan, Vygantas Gruslys, Marina Tadolini, Laurent P. Nicod, Laura Saderi, Alena Aleksa, Mahamadou Bassirou Souleymane, Rafael Laniado-Laborín, Vinicio Manfrin, Jesica Mazza-Stalder, Alberto Piubello, Charalampos Moschos, Liga Kuksa, Alexey Filippov, Giovanni Sotgiu, Lia D'Ambrosio, Agostina Pontarelli, Heinke Kunst, Pietro Viggiani, Jan-Willem C. Alffenaar, Emanuele Pontali, Maurizio Ferrarese, Regina Gayoso, Ieva Gaudiesiute, Onno W. Akkerman, Agnese Šmite, Edvardas Danila, Marie-Christine Payen, Justin T Denholm, Jacinta Drakšienė, Blagovesta Gavazova, Wouter Hoefsloot, Elena Khimova, Dina Visca, Askar Yedilbayev, Nadia Escobar Salinas, Julen Cadiñanos Loidi, Sarai Quirós, Ivan Solovic, Jose A. Caminero, Margareth Pretti Dalcolmo, Apostolos Papavasileiou, Gina Gualano, Birutė Nakčerienė, Martin van den Boom, Lina Davies Forsman, Dmitry Zhurkin, Yang Li, Alena Skrahina, Antonio Spanevello, Cecile Magis-Escurra, Masoud Dara, Selene Manga, Jose Joaquin Cebrian Gallardo, Rosella Centis, Microbes in Health and Disease (MHD), Borisov S., Danila E., Maryandyshev A., Dalcolmo M., Miliauskas S., Kuksa L., Manga S., Skrahina A., Diktanas S., Codecasa L.R., Aleksa A., Bruchfeld J., Koleva A., Piubello A., Udwadia Z.F., Akkerman O.W., Belilovski E., Bernal E., Boeree M.J., Loidi J.C., Cai Q., Gallardo J.J.C., Dara M., Davidaviciene E., Forsman L.D., de Los Rios J., Denholm J., Draksiene J., Duarte R., Elamin S.E., Salinas N.E., Ferrarese M., Filippov A., Garcia A., Garcia-Garcia J.-M., Gaudiesiute I., Gavazova B., Gayoso R., Rosso R.G., Gruslys V., Gualano G., Hoefsloot W., Jonsson J., Khimova E., Kunst H., Laniado-Laborin R., Li Y., Magis-Escurra C., Manfrin V., Marchese V., Robles E.M., Matteelli A., Mazza-Stalder J., Moschos C., Munoz-Torrico M., Hamdan H.M., Nakceriene B., Nicod L., Marcos M.N., Palmero D.J., Palmieri F., Papavasileiou A., Payen M.-C., Pontarelli A., Quiros S., Rendon A., Saderi L., Smite A., Solovic I., Souleymane M.B., Tadolini M., Boom M.V.D., Vescovo M., Viggiani P., Yedilbayev A., Zablockis R., Zhurkin D., Zignol M., Visca D., Spanevello A., Caminero J.A., Alffenaar J.-W., Tiberi S., Centis R., D'Ambrosio L., Pontali E., Sotgiu G., and Migliori G.B.

Subjects
Adult, Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Tuberculosis, Drug-Related Side Effects and Adverse Reactions, Antitubercular Agents, Terizidone, Clofazimine, Antitubercular Agent, Pharmacovigilance, chemistry.chemical_compound, Internal medicine, Tuberculosis, Multidrug-Resistant, medicine, Humans, Prospective Studies, Adverse effect, Aged, business.industry, Middle Aged, medicine.disease, Prospective Studie, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], chemistry, Tolerability, Female, Delamanid, Bedaquiline, Drug-Related Side Effects and Adverse Reaction, business, Human, medicine.drug
Abstract

The World Health Organization (WHO) recommends that countries implement pharmacovigilance and collect information on active drug safety monitoring (aDSM) and management of adverse events.The aim of this prospective study was to evaluate the frequency and severity of adverse events to anti-tuberculosis (TB) drugs in a cohort of consecutive TB patients treated with new (i.e. bedaquiline, delamanid) and repurposed (i.e. clofazimine, linezolid) drugs, based on the WHO aDSM project. Adverse events were collected prospectively after attribution to a specific drug together with demographic, bacteriological, radiological and clinical information at diagnosis and during therapy. This interim analysis included patients who completed or were still on treatment at time of data collection.Globally, 45 centres from 26 countries/regions reported 658 patients (68.7% male, 4.4% HIV co-infected) treated as follows: 87.7% with bedaquiline, 18.4% with delamanid (6.1% with both), 81.5% with linezolid and 32.4% with clofazimine. Overall, 504 adverse event episodes were reported: 447 (88.7%) were classified as minor (grade 1–2) and 57 (11.3%) as serious (grade 3–5). The majority of the 57 serious adverse events reported by 55 patients (51 out of 57, 89.5%) ultimately resolved. Among patients reporting serious adverse events, some drugs held responsible were discontinued: bedaquiline in 0.35% (two out of 577), delamanid in 0.8% (one out of 121), linezolid in 1.9% (10 out of 536) and clofazimine in 1.4% (three out of 213) of patients. Serious adverse events were reported in 6.9% (nine out of 131) of patients treated with amikacin, 0.4% (one out of 221) with ethionamide/prothionamide, 2.8% (15 out of 536) with linezolid and 1.8% (eight out of 498) with cycloserine/terizidone.The aDSM study provided valuable information, but implementation needs scaling-up to support patient-centred care.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results